Paragon Care Limited · ASX:PGC
Paragon Care — Shareholder Meeting (November 2021)
17 slides from Paragon Care's shareholder meeting presentation, Nov 18, 2021
Slide 1: ASX Announcement: AGM Presentation
1300 369 559 [email protected] paragoncare.com.au ASX ANNOUNCEMENT 18 November 2021 Australian Securities Exchange Company Announcements Office AGM Presentation Paragon Care Limited (ASX: PGC) (“PGC” or the “Company”), a leading provider of medical equipment, devices, and consumables to the he
Slide 2: Paragon Care Limited Company Presentation
16 PARAGON CARE LIMITED (ASX: PGC) COMPANY PRESENTATION 18 November 2021
Slide 3: Disclaimer
17 PARAGON CARE DISCLAIMER This presentation has been prepared by Paragon Care Limited (ACN 064 551 426) (Paragon) (ASX: PGC) is current at the date of the presentation, 18 November 2021. This presentation is for information purposes only and is not a prospectus, product disclosure statement or othe
Slide 4: FY21 Overview, Q1 FY22 Update, Merger with Quantum Health Group
18 FY21 OVERVIEW Q1 FY22 UPDATE MERGER WITH QUANTUM HEALTH GROUP (QTM) 18
Slide 5: Established Relationships Across Healthcare
PARAGON CARE 19 ESTABLISHED RELATIONSHIPS ACROSS HEALTHCARE GLOBAL MANUFACTURERS KEY CUSTOMERS Paragon Care Limited (ASX:PGC) 19
Slide 6: FY21 Results: Key Highlights
PARAGON CARE 20 FY21 RESULTS: KEY HIGHLIGHTS Revenue EBITDA NPAT $236m $26.5m $8.3m ↑ 2% on pcp ↑16% on pcp* Diversified revenue streams Improved margins and streamlined operations Represents EPS of 2.45cps in product and geography *Normalised EBITDA OPCF Net Debt DPS $27.5m $69.1m 1.0cps ↑ 419% on
Slide 7: Revenue Stability: Diversified Offering
PARAGON CARE 21 REVENUE STABILITY: DIVERSIFIED OFFERING FY21 Diversified portfolio generated revenue stability DEVICES $85.8m 15% • Devices: Continued growth in eye care DIAGNOSTICS $25.9m 11% • Diagnostics: Expansion of product range • Capital & Consumables: Stable revenue despite difficult CAP
Slide 8: Q1 FY22 Update
22 FY21 OVERVIEW Q1 FY22 UPDATE MERGER WITH QUANTUM HEALTH GROUP (QTM) 22
Slide 9: Q1 FY22 Update
PARAGON CARE 23 Q1 FY22 UPDATE Solid progress in Q1 FY22 in difficult conditions • Revenue stability: Revenue of $56m was down by only 2% on prior year, with continued & in some cases more severe lockdowns across Sydney, Melbourne and NZ during the quarter impacting elective surgery and aged care. •
Slide 10: FY22: Organic Growth Initiatives
PARAGON CARE 24 FY22: ORGANIC GROWTH INITIATIVES • We have a strong growth pipeline with 15 of the largest opportunities across the Group having the potential to increase sales by up to $100M in a 3 - 5 year time frame. • H2 FY22 gradual rebound from NSW, VIC & NZ lockdowns, specifically increased e
Slide 11: Merger with Quantum Health Group (QTM)
25 FY21 OVERVIEW Q1 FY22 UPDATE MERGER WITH QUANTUM HEALTH GROUP (QTM) 25
Slide 12: Strategic Rationale
26 STRATEGIC RATIONALE Cross-Sell • Cross-sell the combined product portfolio into the high growth Asia Pacific markets Growth in Asia Pacific • Enhance growth opportunities in Asia, particularly for Immulab, in Paragon Care’s diagnostics pillar New Suppliers • Attract new suppliers through a larger
Slide 13: A Five Pillar Structure
27 A FIVE PILLAR STRUCTURE DEVICES DIAGNOSTICS CAPITAL & SERVICE & QUANTUM HEALTH CONSUMABLES TECHNOLOGY GROUP EYE CARE BLOOD BANK UROLOGY, CRITICAL CARE MANAGEMENT MEDICAL IMAGING, ORTHOPAEDICS LABORATORY NEONATAL, RADIOLOGY REPORTING & EQUIPMENT & SERVICES MAINTENANCE 30% 9% 36% 6% 19% FY21 Rev *
Slide 14: Established Relationships Across Healthcare
28 ESTABLISHED RELATIONSHIPS ACROSS HEALTHCARE GLOBAL MANUFACTURERS LEADING BRANDS ASIA PACIFIC CUSTOMERS 28
Slide 15: Consolidated FY21 Metrics (Pre-Synergies)
29 CONSOLIDATED FY21 METRICS (Pre-Synergies) FY21 FY21 FY21 Consolidated Consolidated Consolidated Revenue1 EBITDA1 NPBT1 $291m $37m $21m Countries FY21 Gearing Australia Consolidated New Zealand Net Debt/EBITDA2 Ratio2 Korea < 2x 24% Thailand Philippines China Vietnam Notes: (1) Proforma numbers ar
Slide 16: Corporate Overview Post Transaction
30 CORPORATE OVERVIEW POST TRANSACTION Major Shareholders (as at 3 Pro-forma Nov 2021)4 PGC QTM Combined Group Number of shares (m)2 351.40 1,128.31 625.58 Board, Management & 29.1% Market capitalisation (m) $101.2 $79.0 $180.2 Vendors Pre Merger Market Capitalisation (%) 56% 44% 100% China Pioneer
Slide 17: Thank You
31 Shane Tanner Chairman P: 1 300 369 559 E: [email protected] Phil Nicholl Chief Executive Officer P: 1 300 369 559 E: [email protected] THANK YOU Paragon Care Limited (ASX:PGC) 31